CCI study looks at risks for patients with diabetes treated with PCI

09/23/2013 | Healio

Diabetes patients who underwent PCI for STEMI had nearly four times the mortality rate of patients who did not have diabetes, according to results from the INFUSE-AMI trial published in Catheterization and Cardiovascular Interventions. Study participants with diabetes had more extensive left anterior descending artery disease, more comorbidities and a 30-day mortality rate of 8.1%, compared with 2.3% among the group without diabetes. The 30-day revascularization rate was 6.4% for diabetes patients compared with 1% for non-diabetes patients.

View Full Article in:

Healio

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Claims Director
PacificSource
Springfield, OR
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA